// App-Quantinova.ai

OA0023 : ARTEMIS: A European, phase 3, randomised, double‐blind, placebo‐controlled trial of AR101 in peanut‐allergic children and adolescents aged 4‐17

Researchers

Presenter

  • Fernndez-Rivas MM

Principal Investigators

  • Beyer K

  • Turner P

  • Blmchen K

  • Nilsson C

  • Ibez

  • Deschildre A

  • Muraro A

  • Sharma V

  • Erlewyn-Lajeunesse M

  • Zubeldia JM

  • De Blay F

  • Sauvage Delebarre C

  • Byrne A

  • Chapman J

  • Boralevi F

  • Abbas A

  • Norval D

  • Vereda A

  • Mcintosh S

  • Du Toit G

Medical Centers

  • University College Cork, Cork, Ireland

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Imperial College, London, United Kingdom

  • Childrens Hospital, University of Frankfurt, Frankfurt, Germany

  • Clinical Science and Education, Karolina Institutet, Sachs’ Children and Youth Hospital, Sodersjukhuset, Stockholm, Sweden

  • Hospital Infantil Universitario Nino Jesus, Madrid, Spain

  • ARADyAL, Madrid, Spain

  • Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France

  • Food Allergy Referral Centre Veneto Region, Department of Woman and Child Health, Padua University Hospital, Padua, Italy

  • Royal Manchester Children's Hospital & University of Manchester, Manchester, United Kingdom

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • Hospital G.U. Gregorio Marañón, and Biomedical Research Network on Rare Diseases (CIBERER)‐U761, Madrid, Spain

  • University Hospital of Strasbourg, Strasbourg, France

  • Hôpital Saint‐Vincent—Saint Antoine, Lille, France

  • The National Childrens Research Centre, Dublin, Ireland

  • Haematology, James Paget University Hospitals NHS Foundation Trust, Gorleston on sea, United Kingdom

  • Centre Hospitalier Universitaire de Bordeaux, Bordeaux Cedex, France

  • ADC Therapeutics, London, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

Locations

  • Spain

  • Ireland

  • Germany

  • United Kingdom

  • Sweden

  • France

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Anaphylaxis

Biomarkers

  • Immunoglobulin E

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved